Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cholecalciferol Supplementation in Chronic Kidney Disease: Restoration of Vitamin D Status and Impact on Parathyroid Hormone

Full text
Author(s):
Garcia-Lopes, Miriam G. [1] ; Pillar, Roberta ; Kamimura, Maria Ayako [3] ; Rocha, Lillian A. ; Canziani, Maria Eugenia F. ; Carvalho, Aluizio B. ; Cuppari, Lilian [7]
Total Authors: 7
Affiliation:
[1] Univ Fed Sao Paulo. Nutr Program
[3] Univ Fed Sao Paulo. Nutr Program
[7] Univ Fed Sao Paulo. Div Nephrol
Total Affiliations: 7
Document type: Journal article
Source: ANNALS OF NUTRITION AND METABOLISM; v. 61, n. 1, p. 74-82, 2012.
Web of Science Citations: 5
Abstract

Background/Aims: Hypovitaminosis D is highly prevalent among patients with chronic kidney disease (CKD) and has been associated with poor outcome. We aimed to test the effect of a protocol of cholecalciferol supplementation on the restoration of vitamin D status and on parathyroid hormone (PTH) levels in patients with CKD. Methods: This was a prospective interventional study of 6 months. Forty-five CKD patients (stages 3 and 4) with 25-hydroxyvitamin D deficiency {[}25(OH)D <15 ng/ml] were included. Patients received a weekly dose of 50,000 IU of cholecalciferol during 3 months, and 50,000 IU/month thereafter for those who had achieved 25(OH)D >= 30 ng/ml. Results: At 3 months, 78% of the patients restored their vitamin D status. At 6 months, only 43% of those patients maintained adequate vitamin D status. PTH decreased at 3 months (p = 0.02) but returned to baseline levels after 6 months. Fibroblast growth factor 23 increased at 3 months (p = 0.001) and returned to initial levels at 6 months. No changes were found in serum 1,25(OH)(2)D, ionized calcium and phosphorus. Conclusions: A weekly dose of 50,000 IU of cholecalciferol for 3 months restored the vitamin D status of most patients and led to a reduction in PTH. The monthly dose of 50,000 IU appears not to be sufficient to maintain the levels of 25(OH)D. Copyright (C) 2012 S. Karger AG, Basel (AU)

FAPESP's process: 06/03811-6 - Effect of vitamin D2 supplementation on bone mineral metabolism in patients with chronic kidney disease
Grantee:Lilian Cuppari
Support Opportunities: Regular Research Grants